转谷氨酰胺酶2在非小细胞肺癌患者中的预后价值
Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients.
作者信息
Chihong Zhu, Yutian Ling, Danying Wan, Ruibin Jiang, Huaying Sheng, Linhui Gu, Jianguo Feng
机构信息
Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China.
Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China.
出版信息
Oncotarget. 2017 Jul 11;8(28):45577-45584. doi: 10.18632/oncotarget.17374.
Transglutaminase 2 (TG2) plays important roles in cell survival and cancer progression. In this study, we examined TG2 expression in specimen of 194 patients diagnosed with non-small cell lung cancer (NSCLC), and found that the TG2 gene expression was significantly higher in lung cancer tissues as compared to paired incisal marginal tissues or normal tissues. Our data revealed that patients with lower level of TG2 expression detected in cancer tissues had longer disease free survival and overall survival as compared to the patients with higher TG2 expression. We also found that TG2 expression level correlated to NSCLC recurrence. These results suggest a potential prognosis impact of TG2 for NSCLC patients.
转谷氨酰胺酶2（TG2）在细胞存活和癌症进展中发挥着重要作用。在本研究中，我们检测了194例非小细胞肺癌（NSCLC）患者标本中的TG2表达，发现与配对的手术切缘组织或正常组织相比，肺癌组织中的TG2基因表达显著更高。我们的数据显示，与TG2表达较高的患者相比，癌症组织中TG2表达水平较低的患者无病生存期和总生存期更长。我们还发现TG2表达水平与NSCLC复发相关。这些结果表明TG2对NSCLC患者具有潜在的预后影响。
Zotero 插件